NovaBridge Biosciences (NBP)
NASDAQ:NBP
Top Page
NovaBridge Biosciences
(NASDAQ:NBP)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.50
▲(37.80% Upside)
Action:ReiteratedDate:01/07/26
The score is primarily held back by deteriorated financial performance (no 2024 revenue, persistent losses, and ongoing cash burn) despite low leverage. Technicals are mildly bearish with price below key moving averages and a slightly negative MACD, while valuation is largely neutral because negative earnings make the P/E less informative and no dividend support is shown.
Positive Factors
Givastomig Phase 1b efficacy
Robust Phase 1b efficacy and a planned global randomized Phase 2 materially de-risk clinical development for givastomig. Durable impact: if Phase 2 confirms benefit, NovaBridge could secure a best‑in‑class position in CLDN18.2 gastric cancer, enabling partnerships and non-dilutive funding sources.
Negative Factors
Revenue collapsed to zero
Zero product revenue means the company remains pre-commercial and wholly reliant on development milestones and external financing. Over months to years this limits organic funding, increases execution risk for clinical programs, and reduces visibility into self-sustaining operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Givastomig Phase 1b efficacy
Robust Phase 1b efficacy and a planned global randomized Phase 2 materially de-risk clinical development for givastomig. Durable impact: if Phase 2 confirms benefit, NovaBridge could secure a best‑in‑class position in CLDN18.2 gastric cancer, enabling partnerships and non-dilutive funding sources.
Read all positive factors
NovaBridge Biosciences (NBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$292.84M
Dividend YieldN/A
Average Volume (3M)740.92K
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue Growth-100.00%
EPS Growth72.45%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding115,119,490
10 Day Avg. Volume821,454
30 Day Avg. Volume740,922
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-1.31
Enterprise Value/Market Cap1.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.87
Forecast
1Y Price Target
$9.00Price Target Upside254.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
NovaBridge Biosciences Business Overview & Revenue Model
Company Description
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for ...
How the Company Makes Money
I-MAB primarily generates revenue through partnerships and collaborations with other pharmaceutical companies for the development and commercialization of its drug candidates. The company may receive upfront payments, milestone payments, and royal...
NovaBridge Biosciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 4.49M | -10.70M | 88.03M | 1.54B |
| Gross Profit | 0.00 | 0.00 | 4.49M | -248.80M | 41.59M | 1.54B |
| EBITDA | -86.94M | -373.45M | -344.25M | -51.23M | -2.06B | 168.31M |
| Net Income | -66.40M | -162.26M | -1.47B | -2.51B | -2.33B | 470.92M |
Balance Sheet | ||||||
| Total Assets | 1.97B | 212.68M | 2.61B | 4.07B | 5.63B | 6.33B |
| Cash, Cash Equivalents and Short-Term Investments | 1.63B | 173.40M | 2.29B | 3.45B | 670.96M | 733.21M |
| Total Debt | 23.32M | 3.88M | 133.87M | 38.29M | 112.45M | 13.60M |
| Total Liabilities | 131.67M | 11.52M | 894.81M | 1.07B | 1.04B | 706.65M |
| Stockholders Equity | 1.84B | 201.16M | 1.72B | 3.01B | 4.59B | 5.63B |
Cash Flow | ||||||
| Free Cash Flow | 13.15M | -52.72M | -73.02M | -1.15B | -1.00B | 425.55M |
| Operating Cash Flow | 13.15M | -52.67M | -72.85M | -1.10B | -973.09M | 433.56M |
| Investing Cash Flow | -360.38K | -135.97M | -107.63M | 458.38M | -727.21M | -201.90M |
| Financing Cash Flow | 433.38M | -334.89K | -8.25M | 42.36M | 593.92M | 3.44B |
NovaBridge Biosciences Technical Analysis
2.54
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NBP, the sentiment is undefined. The current price of 2.54 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for NBP.
NovaBridge Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
NovaBridge Biosciences Corporate Events
NovaBridge CEO Begins Open-Market Purchases of Company ADSs
Jan 22, 2026
On January 22, 2026, NovaBridge Biosciences disclosed that its chief executive officer and board member, Dr. Sean (Xi‑Yong) Fu, has begun purchasing the company’s American depositary shares in the open market, with an intention to inve...
NovaBridge Biosciences Executive Begins Open-Market ADS Purchases
Jan 22, 2026
On January 21, 2026, NovaBridge Biosciences announced that its Chief Business Development Officer and board member, Dr. Sean Cao, has begun purchasing the company’s American depositary shares in the open market, with plans to buy up to $100,...
NovaBridge Biosciences Executive Chairman Begins Up to $5 Million Open-Market ADS Purchase
Jan 16, 2026
On January 15, 2026, NovaBridge Biosciences’ Executive Chairman Fu Wei began purchasing the company’s American depositary shares in the open market, with an intention to buy up to $5 million worth of ADSs through a controlled entity, t...
NovaBridge Posts Strong Phase 1b Givastomig Data and Prepares Global Phase 2 in First-Line Gastric Cancer
Jan 6, 2026
On January 6, 2026, NovaBridge Biosciences reported updated Phase 1b data showing that its Claudin 18.2 x 4‑1BB bispecific antibody givastomig, in combination with nivolumab and mFOLFOX6 chemotherapy, produced robust objective response rates...
NovaBridge Biosciences Files Nine-Month 2025 Results and Updates Investors on Strategic Transition
Dec 18, 2025
On December 18, 2025, NovaBridge Biosciences reported its results for the nine months ended September 30, 2025, filing a Form 6-K that includes management’s discussion and analysis and unaudited condensed consolidated financial statements. T...
NovaBridge Biosciences Announces Positive Phase 1 Data for Ragistomig at ESMO-IO
Dec 10, 2025
On December 10, 2025, NovaBridge Biosciences presented positive data from a Phase 1 dose expansion study of ragistomig, a bispecific antibody, at the ESMO-IO Congress. The study showed that the new Q6W dosing schedule for ragistomig demonstrated e...
NovaBridge to Present Ragistomig Phase 1 Data at ESMO-IO
Dec 4, 2025
On December 3, 2025, NovaBridge Biosciences announced that data from the expanded Phase 1 study of ragistomig, a bispecific antibody, will be presented at the ESMO-IO Congress on December 10, 2025. The study achieved its objective by demonstrating...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.